Top 20 Vaccines of 2025 

Shots: 

• Vaccines play a critical role in combating infectious diseases by stimulating antibody production and establishing immune memory. Biopharma companies around the globe continue to drive innovation in vaccine development, targeting both infectious and preventable diseases 

• The global vaccine market was valued at $87.75B in 2024 and is projected to reach $151.96B by 2033, reflecting a CAGR of 7.8% from 2025 to 2033. Among leading products, Gardasil/Gardasil‑9 generated $8.58B in revenue, followed by the Prevnar family and Comirnaty 

• PharmaShots presents a concise report on the Top 20 vaccines based on global revenue generated in 2024. 

Note: Columns 1 and 2 represent ranks and products, while Columns 3, 4, and 5 showcase the total vaccine revenue of 2024, the total revenue of 2023, and the percentage change 

20. Synflorix 

Total Revenue: $0.28B 

Company: GSK 

First Approved: US (N/A), EU (Mar 30, 2009) 

Indications Approved: Invasive Disease, Pneumonia, Acute Otitis Media 

• Synflorix, a pneumococcal polysaccharide conjugate vaccine, is designed to prevent invasive infections, pneumonia, and acute otitis media in infants and children aged six weeks to five years 

• The vaccine contains 10 active components, including S. pneumoniae polysaccharide serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F, each conjugated to a carrier protein (mostly protein D, tetanus toxoid, or diphtheria toxoid). The carrier protein helps T-cells and B-cells produce high-affinity antibodies to the polysaccharide antigen 

• In 2024, Synflorix revenue declined by 18.89% compared to 2023. 

19. Priorix 

Total Revenue: $0.4B 

Company: GSK 

First Approved: US (Jun 03, 2022), EU (May 25, 2012) 

Indications Approved: Measles Prophylaxis, Mumps Prophylaxis, Rubella Prophylaxis 

• Priorix is prescribed for active vaccination and prevention of measles, mumps, and rubella (MMR) in children aged 12 months and older 

• Priorix is a lyophilized mixture of attenuated Schwarz measles, RIT 4385 mumps, and Wistar RA 27/3 rubella virus strains. The vaccination protects against MMR by neutralizing antibodies, which stimulate humoral immune responses against the MMR viruses 

• In 2024, Priorix reported a 20.28% increase in revenue compared to 2023. 

18. M-M-R II 

Total Revenue: $0.46B 

Company: Merck 

First Approved: US (1978), EU (N/A) 

Indications Approved: Measles, Mumps, Rubella 

• M-M-R II is a live attenuated vaccine administered from 12 months of age to prevent measles, mumps, and rubella. It is injected intramuscularly or subcutaneously, with a second dose recommended for non-responders  

• The vaccine trains the immune system to recognize weakened forms of these viruses, enabling rapid antibody production upon future exposure 

• In 2024, the revenue of M-M-R II increased by 7.9% compared to 2023, driven primarily by higher US pricing. 

17. Menveo 

Total Revenue: $0.48B 

Company: GSK 

First Approved: US (Feb 19, 2010), EU (Mar 15, 2010) 

Indications Approved: Meningitis 

• Menveo is used for active vaccination against invasive meningococcal illness caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in people aged 2 months to 55 years 

• The vaccine comprises oligosaccharides from four serogroups (A, C, Y, and W-135) conjugated to a protein from the bacteria Corynebacterium diphtheriae. It works by preventing invasive meningococcal illness through the presence of serum bactericidal antibodies 

• In 2024, Menveo’s sales increased slightly by 0.5% compared to 2023 due to favourable delivery timing in international markets and US CDC purchasing patterns. 

16. Fluarix/FluLaval 

Total Revenue: $0.51B 

Company: GSK 

First Approved: US (Dec 14, 2012), EU (Dec 12, 2018) 

Indications Approved: Influenza 

• Fluarix is approved for active vaccination in individuals aged 6 months to 64 years against influenza caused by the influenza A and B virus subtypes 

• Fluarix is an inactivated influenza vaccine comprising antigens grown in embryonated eggs and administered via intramuscular injection. The vaccination develops protection against the influenza virus by boosting the creation of disease-specific antibodies 

• In 2024, Fluarix’s sales declined by 20.11% compared to 2023, due to competitive pressure and reduced US demand. 

15. Infanrix/Pediarix 

Total Revenue: $0.64B 

Company: GSK 

First Approved: US (Jul 08, 2003), EU (Oct 23, 2000) 

Indications Approved: Diphtheria, Tetanus, Pertussis, Polio, Hepatitis B, Haemophilus Influenza Type B 

• Infanrix is approved for active immunization against diphtheria, tetanus, and pertussis in children aged 6 weeks to 6 years (5-dose series) 

• Pediarix is indicated for vaccination against diphtheria, tetanus, pertussis, and all known subtypes of hepatitis B virus. Both vaccines stimulate antibody production and immune memory 

• In 2024, revenue for Infanrix/Pediarix declined by 8.79% compared to 2023 due to adverse CDC stockpile movements. 

14. RotaTeq 

Total Revenue: $0.71B 

Company: Merck & Co. 

First Approved: US (Feb 03, 2006), EU (Jun 27, 2006) 

Indications Approved: Rotavirus Vaccine 

• RotaTeq prevents rotavirus gastroenteritis caused by G1, G2, G3, G4, and G9 strains in infants aged 6 to 32 weeks 

• The vaccine contains a live, attenuated virus that replicates in the gut and interacts with the immune system to build immunity 

• In 2024, RotaTeq revenue declined by 7.54% compared to 2023 due to lower sales in the US and international markets. 

13. Rotarix 

Total Revenue: $0.73B 

Company: GSK 

First Approved: US (Apr 03, 2008), EU (Feb 21, 2006) 

Indications Approved: Rotavirus 

• Rotarix prevents rotavirus gastroenteritis caused by both G1 and non-G1 strains (G3, G4, and G9) 

• Rotarix is a live attenuated rotavirus vaccine developed from the human 89-12 strain of the G1P type. Because the precise method by which Rotarix works is uncertain, it is assumed that the vaccine triggers neutralizing antibodies to boost immunity 

• In 2024, Rotarix revenue decreased by 5.65% compared to 2023 due to adverse CDC stockpile movements. 

12. Arexvy 

Total Revenue: $0.74B 

Company: GSK 

First Approved: US (May 03, 2023), EU (Jun 06, 2023) 

Indications Approved: LRTD caused by Respiratory Syncytial Virus (RSV) 

• Arexvy is an RSV vaccine for adults aged 60+, and for those aged 50–59 at increased risk of RSV-related lower respiratory tract disease (LRTD) 

• It contains the RSVPreF3 protein, which stimulates immune recognition and protection against RSV 

• In 2024, Arexvy revenue decreased by 52.96% compared to 2023 due to market pressures in the US and China. 

11. Abrysvo 

Total Revenue: $0.75B 

Company: Pfizer 

First Approved: US (May 31, 2023), EU (Aug 23, 2023) 

Indications Approved: LRTD and severe LRTD caused by RSV 

• Abrysvo is used to prevent RSV-related LRTD in adults 18+, pregnant women (weeks 24–36), and infants from birth to 6 months 

• It contains stabilized prefusion F proteins from RSV subgroups A and B to trigger protective immune responses 

10. Vaxneuvance 

10. Vaxneuvance 

Total Revenue: $0.8B 

Company: Merck & Co. 

First Approved: US (July 16, 2021), EU (Dec 13, 2021) 

Indications Approved: Pneumococcal Infections 

• Vaxneuvance is a pneumococcal vaccine indicated from 6 weeks of age for the prevention of invasive disease caused by 15 S. pneumoniae serotypes 

• It combines polysaccharides conjugated to a carrier protein with an aluminum-based adjuvant to enhance immunity 

• In 2024, revenue increased by 21.5% compared to 2023, driven by pediatric uptake in Europe, Japan, and Asia Pacific. 

9. Boostrix 

Total Revenue: $0.85B

Company: GSK 

First Approved: US (May 03, 2005), EU (Sep 24, 2010) 

Indications Approved: Diphtheria, Tetanus, Acellular Pertussis Booster 

• Boostrix is a sterile vaccine for booster immunization against tetanus, diphtheria, and pertussis in people aged 10 and above 

• It is also used during the third trimester of pregnancy to help protect infants under two months old 

• In 2024, Boostrix revenue increased by 9.45% compared to 2023, supported by higher US market share and European demand. 

8. ProQuad 

Total Revenue: $0.92B 

Company: Merck & Co. 

First Approved: US (Sep 06, 2005), EU (Apr 05, 2006) 

Indications Approved: Measles, Mumps, Rubella, Varicella 

• ProQuad is a combination vaccine for measles, mumps, rubella, and varicella from 12 months of age 

• The vaccine contains weakened forms of the viruses, with a second dose often required for full protection against chickenpox and measles in young children 

• In 2024, ProQuad revenue increased by 5.74% compared to 2023, mainly due to higher US pricing. 

7. Varivax 

Total Revenue: $1.1B 

Company: Merck & Co. 

First Approved: US (Mar 17, 1995), EU (Apr 21, 2021) 

Indications Approved: Active Immunization of Varicella (Chickenpox) 

• Varivax prevents varicella in children aged 12 months and older 

• Varivax contains a live, attenuated strain of the varicella-zoster virus (Oka/Merck strain), stimulating protective immunity 

• In 2024, Varivax revenue increased by 3.18% compared to 2023, driven by higher US pricing. 

6. Bexsero 

Total Revenue: $1.34B 

Company: GSK 

First Approved: US (Jan 23, 2015), EU (Jan 14, 2013) 

Indications Approved: Meningitis 

• Bexsero is a multicomponent meningococcal serogroup B vaccine that induces antibodies against NHBA, NadA, fHbp, and PorA P1.4 surface proteins 

• The vaccination protects against invasive meningococcal disease, mostly by complement-mediated antibody-dependent death of N. meningitidis  

• In 2024, Bexsero revenue increased by 24.07% compared to 2023, driven by demand in Germany and Australia. 

5. Spikevax (mRNA-1273) 

Total Revenue: $3.1B 

Company: Moderna 

First Approved: US (Jan 31, 2022, EU (Oct 3, 2022) 

Indications Approved: Spikevax: COVID-19 

• Spikevax is an mRNA vaccine administered from 6 months of age in two intramuscular doses, 28 days apart 

• Spikevax delivers mRNA encoding the spike protein of SARS-CoV-2, prompting antibody and T-cell responses 

• In 2024, revenue declined by 53.73% compared to 2023 due to reduced COVID-19 vaccine demand.

4. Shingrix 

4. Shingrix 

Total Revenue: $4.27B 

Company: GSK 

First Approved: US (Mar 21, 2018), EU (Oct 20, 2017) 

Indications Approved: Herpes Zoster (Shingles) 

• Shingrix is a recombinant, non-live vaccine for shingles and postherpetic neuralgia in adults over 19 years 

• Shingrix induces strong, sustained immune responses against varicella-zoster virus 

• In 2024, Shingrix revenue declined by 2.51% compared to 2023 due to lower sales in China. 

3. Comirnaty 

3. Comirnaty 

Total Revenue: $5.35B 

Company: Pfizer, BioNTech 

First Approved: US (Aug 23, 2021), EU (Oct 10, 2022) 

Indications Approved: COVID-19 

• Comirnaty is a vaccine used for active immunization against COVID-19 caused by SARS-CoV-2 in people aged 12 and above  

• The lipid-encapsulated mRNA encodes the SARS-CoV-2 S antigen, triggering neutralizing antibodies and cellular immune responses 

• In 2024, Comirnaty sales decreased by 52.29% compared to 2023 due to reduced COVID-19 vaccine demand. 

2. Prevnar Family 

2. Prevnar Family 

Total Revenue: $6.41B 

Company: Pfizer, Daewoong 

First Approved: US (Prevnar 13: Feb 24, 2010; Prevnar 20: Jun 08, 2021), EU (Prevnar 13: Feb 14, 2022; Prevnar 20: Dec 09, 2009) 

Indications Approved: Pneumococcal Disease Prophylaxis 

• The Prevnar Family includes Prevnar 13 and Prevnar 20, both inducing T-cell–dependent immune responses via polysaccharides conjugated to carrier proteins 

• Prevnar 13 covers 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A 19F, and 23); Prevnar 20 expands coverage to 20 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) 

• In 2024, Prevnar revenue declined by 1.38% compared to 2023 due to lower US and international sales.

1. Gardasil & Gardasil-9 

1. Gardasil & Gardasil-9 

Total Revenue: $8.58B 

Company: Merck & Co. 

First Approved: US (Gardasil-Jun 06, 2006; Gardasil-9- Dec 10, 2014), EU (Gardasil- Sep 20, 2006; Gardasil-9- Jun 10, 2015) 

Indications Approved: Gardasil – Human Papillomavirus Vaccines and Gardasil-9 – Human Papill 

• Gardasil (quadrivalent) is indicated for HPV types 6, 11, 16, and 18 in individuals aged 9 – 26 

• Gardasil-9 (9-valent) covers HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in individuals aged 9–45. Both stimulate humoral immune responses 

• In 2024, Gardasil and Gardasil-9 revenue decreased by 3.4% compared to 2023 due to reduced demand in China. 

Sources:    

• Annual reports  

• SEC Filings  

• Press releases  

• Company websites  

Currency Conversion: Oanda (£1 – $1.25)  

Related Posts: Top 20 Vaccines of 2024